Skip to main content
SpringerLink
Log in

Effect of Formulation Variables on the Nasal Permeability and Stability of Naloxone Intranasal Formulations

  • Research Article
  • Theme: NIPTE on Current Topics in Abuse Deterrent Science
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Naloxone is an opioid antagonist with high affinity for μ-opioid receptor, and for this reason it is used for the emergency treatment of opioid overdose. Originally, it was available only as an injectable product. However, for the ease of administration, intranasal (IN) formulations have also become available. These IN formulations contain preservatives and stabilizers such as benzalkonium chloride (BKC), benzyl alcohol (BA), and ethylenediaminetetraacetic acid (EDTA). Some of these ingredients are known to affect permeability of drugs. This study focuses on investigating the effect of formulation variables including choice of preservatives, stabilizer, and pH on the permeability and stability of naloxone IN formulations. The in vitro permeability of naloxone was evaluated employing EpiAirway™ tissue-mounted Ussing chambers. BKC was found to enhance the apparent permeability (Papp) of naloxone significantly (p < 0.05) at very low concentration, while BA caused similar enhancement at a much higher concentration. EDTA was found to decrease Papp of naloxone by lowering the pH, and thePapp of naloxone was found to decrease approximately 51-fold with the decrease in formulation pH from 6.0 to 4.0. The product stability was, however, found optimal only below pH 5.0. Thus, selection of formulation ingredients, buffering agent, and pH of IN formulation is a balancing act for achieving desired permeability and optimal stability to achieve reasonable shelf life of naloxone IN formulation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Overdose death rates. National Institute on Drug Abuse. Available from: https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. Accessed 16 Apr 2019.

  2. Haddox JD. Opioids with abuse-deterrent properties: a regulatory and technological overview. J Opioid Manag. 2017;13(6):397–413.

    Article  Google Scholar 

  3. Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol. 2017;58:143–59.

    Article  Google Scholar 

  4. Lewis CR, Vo HT, Fishman M. Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review. Subst Abus Rehabil. 2017;8:79–95. https://doi.org/10.2147/SAR.S101700.

    Article  Google Scholar 

  5. Wolfe TR, Bernstone T. Intranasal drug delivery: an alternative to intravenous administration in selected emergency cases. J Emerg Nurs. 2004;30(2):141–7. https://doi.org/10.1016/j.jen.2004.01.006.

    Article  PubMed  Google Scholar 

  6. Robertson TM, Hendey GW, Stroh G, Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp Emerg Care. 2009;13(4):512–5. https://doi.org/10.1080/10903120903144866.

    Article  PubMed  Google Scholar 

  7. Merlin MA, Saybolt M, Kapitanyan R, Alter SM, Jeges J, Liu J, et al. Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. Am J Emerg Med. 2010;28(3):296–303. https://doi.org/10.1016/j.ajem.2008.12.009.

    Article  PubMed  Google Scholar 

  8. Press release: Indivior receives complete response letter from FDA not approving naloxone nasal spray new drug application for opioid overdose 2015. Available from: http://indivior.com/wp-content/uploads/2015/11/Nasal-Naloxone-Final-Release_1124151.pdf. Accessed 16 Apr 2019.

  9. Press Release: Amphastar announces the receipt of a CRL for intranasal naloxone for the emergency treatment of opioid overdose 2017. Available from: http://ir.amphastar.com/static-files/19b13150-7ff8-4d3b-8e3f-452578083dbb. Accessed 16 Apr 2019.

  10. Hertz S., Narcan nasal spray summary review for regulatory action US Food and Drug Administration. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208411Orig1s000SumR.pdf. Accessed 16 Apr 2019.

  11. Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009;104(12):2067–74.

    Article  Google Scholar 

  12. McDonald R, Danielsson Glende Ø, Dale O, Strang J. International patent applications for non-injectable naloxone for opioid overdose reversal: exploratory search and retrieve analysis of the PatentScope database. Drug Alcohol Rev. 2018;37(2):205–15. https://doi.org/10.1111/dar.12571.

    Article  PubMed  Google Scholar 

  13. Adapt Pharma Inc. Narcan - naloxone hydrochloride spray In: Drugs@FDA: FDA approve drug products. Adapt Pharma Inc. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf. Accessed 16 Apr 2019.

  14. Keegan F, Bell RG, Crystal R, Weiss MB. Nasal drug products and methods of their use. US Patent. 2017;9,775,838.

  15. Crystal R, Weiss MB. Nasal drug products and methods of their use. US Patent. 2015;9,211,253.

  16. Sharma S, Kulkarni J, Pawar A. Permeation enhancers in the transmucosal delivery of macromolecules. Pharmazie. 2006;61(6):495–504.

    CAS  PubMed  Google Scholar 

  17. Wyse J, DeHart MP. Intranasal naloxone compositions and methods of making and using same. US Patent. 2015;9,192,570.

  18. Tylleskar I, Skulberg AK, Nilsen T, Skarra S, Jansook P, Dale O. Pharmacokinetics of a new, nasal formulation of naloxone. Eur J Clin Pharmacol. 2017;73(5):555–62. https://doi.org/10.1007/s00228-016-2191-1.

    Article  CAS  PubMed  Google Scholar 

  19. McDonald R, Lorch U, Woodward J, Bosse B, Dooner H, Mundin G, et al. Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study. Addiction. 2018;113(3):484–93. https://doi.org/10.1111/add.14033.

    Article  PubMed  Google Scholar 

  20. Mundin G, McDonald R, Smith K, Harris S, Strang J. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction. 2017;112(9):1647–52. https://doi.org/10.1111/add.13849.

    Article  PubMed  Google Scholar 

  21. Wheatley M, Dent J, Wheeldon E, Smith P. Nasal drug delivery: an in vitro characterization of transepithelial electrical properties and fluxes in the presence or absence of enhancers. J Control Release. 1988;8(2):167–77.

    Article  CAS  Google Scholar 

  22. Bechgaard E, Gizurarson S, Jørgensen L, Larsen R. The viability of isolated rabbit nasal mucosa in the Ussing chamber, and the permeability of insulin across the membrane. Int J Pharm. 1992;87(1–3):125–32.

    Article  CAS  Google Scholar 

  23. Chemuturi NV, Hayden P, Klausner M, Donovan MD. Comparison of human tracheal/bronchial epithelial cell culture and bovine nasal respiratory explants for nasal drug transport studies. J Pharm Sci. 2005;94(9):1976–85.

    Article  CAS  Google Scholar 

  24. Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC, Costantino HR. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. J Pharm Sci. 2005;94(8):1736–46. https://doi.org/10.1002/jps.20389.

    Article  CAS  PubMed  Google Scholar 

  25. Van Breemen RB, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1(2):175–85.

    Article  Google Scholar 

  26. Hispira, Inc. Naloxone hydrochloride- naloxone hydrochloride injection, solution. In: FDA Label Search Available from: https://www.accessdata.fda.gov/spl/data/a91e6c30-fb00-4ae0-be36-ccd1f2363e15/a91e6c30-fb00-4ae0-be36-ccd1f2363e15.xml. Accessed 16 Apr 2019.

  27. Mylan Institutional LLC. Naloxone hydrochloride- naloxone hydrochloride injection, solution. In: FDA Label Search. Available from: https://www.accessdata.fda.gov/spl/data/69401599-0f6a-4055-9dde-0e57d66afe93/69401599-0f6a-4055-9dde-0e57d66afe93.xml. Accessed 16 Apr 2019.

  28. Marttin E, Verhoef J, Romeijn S, Zwart P, Merkus F. Acute histopathological effects of benzalkonium chloride and absorption enhancers on rat nasal epithelium in vivo. Int J Pharm. 1996;141(1–2):151–60.

    Article  CAS  Google Scholar 

  29. Fabrizio B, Giulia BA, Fabio S, Paola R, Gaia C. In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: the enhancing effect of potassium sorbate. Eur J Pharm Sci. 2009;37(1):36–42.

    Article  CAS  Google Scholar 

  30. Cho E, Gwak H, Chun I. Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm. 2008;349(1):101–7.

    Article  CAS  Google Scholar 

  31. Tomita M, Hayashi M, Awazu S. Comparison of absorption-enhancing effect between sodium caprate and disodium ethylenediaminetetraacetate in Caco-2 cells. Biol Pharm Bull. 1994;17(5):753–5.

    Article  CAS  Google Scholar 

  32. Tomita M, Hayashi M, Awazu S. Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. J Pharm Sci. 1996;85(6):608–11. https://doi.org/10.1021/js9504604.

    Article  CAS  PubMed  Google Scholar 

  33. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S, Couderc L-J, et al. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol Ther. 2012;134(3):366–79.

    Article  CAS  Google Scholar 

  34. England RJ, Homer JJ, Knight LC, Ell SR. Nasal pH measurement: a reliable and repeatable parameter. Clin Otolaryngol Allied Sci. 1999;24(1):67–8.

    Article  CAS  Google Scholar 

  35. Cho DY, Hwang PH, Illek B, Fischer H. Acid and base secretion in freshly excised nasal tissue from cystic fibrosis patients with ΔF508 mutation. Int Forum Allergy Rhinol. 2011;1(2):123–7. https://doi.org/10.1002/alr.20028.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Washington N, Steele R, Jackson S, Bush D, Mason J, Gill D, et al. Determination of baseline human nasal pH and the effect of intranasally administered buffers. Int J Pharm. 2000;198(2):139–46.

    Article  CAS  Google Scholar 

  37. Inactive ingredient database U.S. Food and Drug Administration. 2018. Available from: https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed 16 Apr 2019.

Download references

Author information

Author notes

  1. Ciby Abraham

    Present address: AstraZeneca, One Medimmune Way, Gaithersburg, Maryland, 20878, USA

Authors and Affiliations

  1. Division of Product Quality Research, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, 20993, USA

    Hao-Jui Hsu, Yang Yang, Muhammad Ashraf & Manar Al-Ghabeish

  2. Division of New Drug Product II, Office of New Drug Product, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, 20993, USA

    Venkateswara Pavuluri & Ciby Abraham

  3. Division of Clinical Pharmacology II, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, Maryland, 20993, USA

    Suresh Babu Naraharisetti

Authors
  1. Hao-Jui Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Venkateswara Pavuluri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ciby Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Suresh Babu Naraharisetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Muhammad Ashraf
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manar Al-Ghabeish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manar Al-Ghabeish.

Ethics declarations

Disclaimer

This manuscript reflects the views of the authors and should not be construed to represent FDA’s views or policies.

Additional information

Guest Editors: Heather Boyce, Steve R. Byrn, and Stephen W. Hoag

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hsu, HJ., Yang, Y., Pavuluri, V. et al. Effect of Formulation Variables on the Nasal Permeability and Stability of Naloxone Intranasal Formulations. AAPS PharmSciTech 20, 232 (2019). https://doi.org/10.1208/s12249-019-1452-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12249-019-1452-6

KEY WORDS

Search

Navigation